Moderna is no longer priced as a leftover pandemic cash pile. The August late-stage win for intismeran autogene, the individualized melanoma shot developed with Merck, recast the equity as a platform story rather than a runoff franchise. That readout is the first successful pivotal test of a personalized neoantigen medicine and the first time an mRNA cancer regimen beat pembrolizumab alone after surgery. The market responded by lifting the name from the low twenties to a capitalization near $61 billion. The debate is whether that re-rating is earned by a durable oncology franchise or is still a single-trial option sitting on a seasonal vaccine P&L that burns cash.
The commercial business underneath that re-rating remains a winter franchise. Mid-year product sales were still a thin $94 million in a seasonally quiet quarter, and full-year sales last year were under $2 billion after a forty percent collapse. Management is targeting growth of as much as ten percent this year, helped by United Kingdom partnership deliveries, a European RSV tender, and the early-August approval of mFLUSIVA, the first licensed mRNA flu shot for adults fifty and older. Those launches are real products rather than slideware from a conference deck. They do not yet cover a research budget still running near $3 billion a year, and the March settlement with Arbutus and Genevant took $950 million of cash in July to buy peace on lipid-nanoparticle patents.
Cash at mid-year was about $7 billion before that settlement check. The subsequent zero-coupon convertible, sized at $2600 million and due in 2032, restocked the balance sheet after the melanoma rally and bought time to fund an oncology build. What resolves the case over the next year is not another light summer print. It is whether flu and combination launches lift the respiratory run-rate, whether regulators take the melanoma file seriously, and whether cash at year-end lands in the guided $5 billion area rather than sliding faster. Does the equity still work if intismeran is a melanoma-only product and respiratory demand keeps fading?